Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

Bibliographic Details
Main Authors:	William L Redmond, Annah S Rolig, Daniel C Rose, Saul Kivimae, Werner Rubas, Grace Helen McGee
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/4/e004218.full

Internet